Conclusion

MS treatment must be carefully tailored to each patient. The choice of DMT should take into account “the individual patient’s needs and lifestyle, and how the specific requirements and characteristics of the drug intersect with the individual patient’s profile.”4 Interventions designed to maximize medication adherence in patients with MS need to “incorporate new and creative approaches that take individual patient needs and lifestyle into account.”4

References


Continue Reading

1.     Turner AP, Roubinov DS, Atkins DC, Haselkorn JK. Predicting medication adherence in multiple sclerosis using telephone-based home monitoring. Disabil Health J. 2015 Sep 5. [Epub ahead of print]

2.     Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30(2):89-100.

3.     Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011 Jan;28(1):51-61.

4.     Remington G, Rodriguez Y, Logan D, et al. Facilitating medication adherence in patients with multiple sclerosis. Int J MS Care. 2013;15:36-45.

5.     Brunton SA. Improving medication adherence in chronic disease management. J Fam Pract. 2011;60(4 Suppl) S1-S8.

6.     World Health Organization (WHO). Adherence to long-term therapies: evidence for action. (2003) Available at: http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf. Accessed: December 9, 2015.

7.     Wong J, Gomes T, Mamdani M, et al. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low. Can J Neurol Sci. 2011 May;38(3):429-33.

8.     Saiz A, Mora S, Blanco J, et al. Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study. Neurologia. 2015 May;30(4):214-22.

9.     Rieckmann P, Boyko A, Centonze D, et al. Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. Mult Scler Relat Disord. 2015 May;4(3):202-18.

10.  Costello K, Kennedy P, Scanzillo J. recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med. 2008;10(9):225.

11.  Bruce JM, Hancock LM, Lynch SG. Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report. Mult Scler. 2010  Jan;16(1):112-20.

12.  Sola-Valls N, Blanco Y, Sepúlveda M, et al. Telemedicine for monitoring MS activity and progression. Curr Treat Options Neurol. 2015 Nov;17(11):47.

13.  Poulos C, Kinter E, Yang JC, Bridges JF, Posner J, Reder AT. Patient preferences for injectable treatments for multiple sclerosis in the United States: a discrete-choice experiment. Patient. 2015 Aug 11. [Epub ahead of print]

14.  Kim W, Zandoná ME, Kim S-H, Kim HJ. Oral disease-modifying therapies for multiple sclerosis. J Clin Neurol. 2015 Jan; 11(1): 9–19.

15.  Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis – a review of approved medications. Eur J Neurol. 2016 Jan;23 Suppl1:18-27.

16.  Mohr DC, Cox D, Epstein L, Boudewyn A. Teaching patients to self-inject: pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications. J Behav Ther Exp Psychiatry. 2002 Mar;33(1):39-47.